Search results for "Unstable"

showing 10 items of 111 documents

Short-and long-term outcome after PTCA in patients with stable and unstable angina

1990

Acute results and follow-up data over a period of 36 months after attempted PTCA in 406 patients with stable angina and 202 patients with unstable angina are reported. The rate of acute complications (death, myocardial infarction and bypass grafting (CABG) amounted to 1.5% in stable and 6.4% in unstable patients (P less than 0.005). Within the first week after PTCA a significantly lower percentage (1.7% vs 10.4%) of cardiac events (death, myocardial infarction, CABG and repeat PTCA) was observed in the stable group (P less than 0.001). During a 12-month follow-up period, another 16.3% of the patients in the stable group and 30.7% of unstable patients suffered a new cardiac event (P less tha…

AdultMalemedicine.medical_specialtyBypass graftingMyocardial InfarctionAsymptomaticAngina PectorisPostoperative ComplicationsInternal medicinemedicineHumansIn patientAngina Unstablecardiovascular diseasesMyocardial infarctionAngioplasty Balloon CoronaryCoronary Artery BypassMedical treatmentUnstable anginabusiness.industryIncidence (epidemiology)Middle AgedPrognosismedicine.diseaseQuality of LifeCardiologyFemalemedicine.symptomCardiology and Cardiovascular MedicinebusinessEarly phaseFollow-Up StudiesEuropean Heart Journal
researchProduct

Advantages of immediate two-dimensional echocardiography in patients with acute cardiac ischemic events

1995

Abstract We hypothesized that the assessment of kinetic alterations on two dimensional echocardiogram (2DE) would provide greater diagnostic information than clinical symptoms and ECG changes only. The study was aimed to determine sensitivity of 2DE in patients with cardiac ischemic events and to improve the indications to thrombolysis. Three-hundred ninety-one patients (87 F; 304 M) hospitalized for suspected acute myocardial infarction (AMI), first episode, within 4 h from the onset of symptoms, suitable for thrombolysis Killip class I–II and with unstable angina (UA), were admitted in the study. Patients had to show ECG changes and alterations of segmentary motion on 2DE performed at ent…

AdultMalemedicine.medical_specialtySystolemedicine.medical_treatmentMyocardial InfarctionMyocardial IschemiaIschemiaInfarctionSensitivity and SpecificityVentricular Function LeftElectrocardiographyFibrinolytic AgentsInternal medicinemedicineHumansThrombolytic TherapyAngina Unstablecardiovascular diseasesMyocardial infarctionAngioplasty Balloon CoronaryCoronary Artery BypassCreatine KinaseAgedKillip classAged 80 and overFirst episodeHeparinVascular diseaseUnstable anginabusiness.industryThrombolysisMiddle Agedmedicine.diseaseIsoenzymesSurvival RateEchocardiographyVentricular Function RightCardiologyFemaleCardiology and Cardiovascular MedicinebusinessInternational Journal of Cardiology
researchProduct

The value of N-terminal fragment of brain natriuretic peptide and tissue inhibitor of metalloproteinase-1 levels as predictors of cardiovascular outc…

2008

Aims We sought to determine the association between two major biomarkers, the inactive N-terminal fragment of brain natriuretic peptide (NT-proBNP) and tissue inhibitor of metalloproteinase-1 (TIMP-1) and long-term cardiovascular outcomes in a cohort of subjects who had a myocardial infarction or unstable angina 3–36 months previously. Methods and results Plasma NT-proBNP and TIMP-1 were measured in a nested case control study of 250 randomly matched subject pairs enrolled in the long-term intervention with pravastatin in ischaemic disease (LIPID) and LIPID extended follow-up studies. Cases ( n = 250) were defined as those who had a cardiovascular death, non-fatal myocardial infarction or s…

AdultMalemedicine.medical_specialtymedicine.drug_classMyocardial InfarctionCoronary AngiographyGastroenterologyLeukocyte CountRisk FactorsInternal medicineNatriuretic Peptide BrainmedicineNatriuretic peptideHumansAngina UnstableAgedPravastatinTissue Inhibitor of Metalloproteinase-1Framingham Risk Scorebusiness.industryAnticholesteremic AgentsCase-control studyOdds ratioMiddle AgedPrognosisBrain natriuretic peptidePeptide FragmentsC-Reactive ProteinEndocrinologyQuartileCase-Control StudiesNested case-control studyFemaleCardiology and Cardiovascular MedicinebusinessBiomarkersPravastatinmedicine.drugEuropean Heart Journal
researchProduct

Impact of routine angiographic follow-up after angioplasty

1998

Abstract Background There is an ongoing controversy as to whether repeat coronary angiography should be routinely performed after successful percutaneous transluminal coronary angioplasty (PTCA). Methods We examined the 10-year outcome in 400 patients who had or had not undergone an angiographic control 6 months after successful PTCA and a subsequent event-free 6-month period. Our comparison was based on data gathered by questionnaire and telephone interview in 315 patients with (group A) and 85 patients without (group B) a routine 6-month angiographic control. Multivariate analysis (Cox model) was performed to identify predictors of adverse events. Results During the 10-year follow-up peri…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentMyocardial InfarctionUnnecessary ProceduresCoronary AngiographyDisease-Free SurvivalSurveys and QuestionnairesInternal medicineAngioplastyHumansMedicineLife Tablescardiovascular diseasesMyocardial infarctionAngioplasty Balloon CoronaryAdverse effectAgedProportional Hazards Modelsbusiness.industryProportional hazards modelUnstable anginaMortality rateMiddle Agedmedicine.diseaseSurgerymedicine.anatomical_structureBypass surgeryCardiologyFemaleCardiology and Cardiovascular MedicinebusinessArteryAmerican Heart Journal
researchProduct

Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris

1996

Percutaneous transluminal coronary angioplasty is often complicated by thrombotic abrupt vessel closure in patients with unstable angina pectoris. The present multicentre trial was performed to determine the feasibility of two-dose regimens of recombinant hirudin (r-hirudin) compared to standard heparin in patients undergoing coronary angioplasty for unstable angina, and to investigate the effects of the different treatment regimen on markers of coagulation activation. At five participating centres, 61 patients were randomly enrolled in one of two sequential groups of r-hirudin (group 1: 0.3 mg.kg-1 i.v. bolus, 0.12 mg.kg-1.h-1 i.v. infusion; 21 patients; group 2: 0.5 mg.kg-1 i.v. bolus, 0.…

Adultmedicine.drug_classmedicine.medical_treatmentHirudinEnzyme-Linked Immunosorbent AssayAnginaFibrinolytic AgentsmedicineHumansAngina UnstableAngioplasty Balloon CoronaryInfusions IntravenousBlood CoagulationAgedBlood coagulation testDose-Response Relationship Drugmedicine.diagnostic_testHeparinUnstable anginabusiness.industryAnticoagulantThrombinAnticoagulantsPercutaneous coronary interventionHeparinHirudinsMiddle Agedmedicine.diseaseRecombinant ProteinsAnesthesiaPartial Thromboplastin TimeDrug MonitoringCardiology and Cardiovascular MedicinebusinessBiomarkersmedicine.drugPartial thromboplastin timeEuropean Heart Journal
researchProduct

Genetic and pharmacological modulation of DNA mismatch repair heterogeneous tumors promotes immune surveillance.

2023

Patients affected by colorectal cancer (CRC) with DNA mismatch repair deficiency (MMRd), often respond to immune checkpoint blockade therapies, while those with mismatch repair-proficient (MMRp) tumors generally do not. Interestingly, a subset of MMRp CRCs contains variable fractions of MMRd cells, but it is unknown how their presence impacts immune surveillance. We asked whether modulation of the MMRd fraction in MMR heterogeneous tumors acts as an endogenous cancer vaccine by promoting immune surveillance. To test this hypothesis, we use isogenic MMRp (Mlh1+/+) and MMRd (Mlh1-/-) mouse CRC cells. MMRp/MMRd cells mixed at different ratios are injected in immunocompetent mice and tumor reje…

Cancer Research6-thioguaninemismatch repairOncology6-thioguanine; heterogeneity; immune checkpoint blockade; immune evasion; immune surveillance; microsatellite unstable tumors (MSI); mismatch repair; temozolomide6-thioguanine heterogeneity immune checkpoint blockade immune evasion immune surveillance microsatellite unstable tumors (MSI) mismatch repair temozolomideimmune surveillancemicrosatellite unstable tumors (MSI)temozolomideheterogeneityimmune checkpoint blockadeSettore MED/08 - Anatomia Patologicaimmune evasionCancer cell
researchProduct

Langzeitverlauf über 10 Jahre nach Ballondilatation bei stabiler und instabiler Angina pectoris

2008

OBJECTIVE To assess the cardiac status of patients ten years after percutaneous transluminal coronary artery angioplasty (PTCA). PATIENTS AND METHODS Data of 534 patients (436 men, 98 women; mean age 53.2 +/- 8 years) in whom a PTCA had been performed between 1983 and 1986 were analysed, based on a questionnaire answered 121 +/- 11 months after the initial procedure. At the time of PTCA 184 patients (35%) had unstable angina, 350 (65%) stable angina. RESULTS 116 patients (63%) with unstable angina and 164 (47%) with stable angina had at least one cardiac event after the initial PTCA (repeat PTCA, bypass operation, myocardial infarction, death). None of these events occurred in 68 patients (…

Cardiovascular eventmedicine.medical_specialtyPercutaneousbusiness.industryUnstable anginaGeneral Medicinemedicine.diseasesurgical procedures operativeBypass operationInternal medicineCardiologyMedicineCoronary artery angioplastyIn patientcardiovascular diseasesMyocardial infarctionbusinessCardiac statusDMW - Deutsche Medizinische Wochenschrift
researchProduct

Endothelial dysfunction and carotid lesions are strong predictors of clinical events in patients with early stages of atherosclerosis: a 24-month fol…

2008

Background The purpose of this study was to investigate whether the vasodilator response to brachial artery and the presence of carotid lesions may have a prognostic significance in patients with early stages of atherosclerosis. Methods and results Vascular echography was performed to analyze flow-mediated vasodilatation (FMD) at the brachial artery and intima–media thickness (IMT) of carotid arteries in 84 asymptomatic patients. At baseline, we evaluated all the established traditional cardiovascular risk factors. Transient ischemic attack, stroke, effort or unstable angina, acute myocardial infarction, peripheral arterial disease and cerebrovascular and cardiovascular death served as outc…

Carotid Artery DiseasesMalemedicine.medical_specialtyBrachial ArteryAsymptomaticCoronary artery diseaseSex FactorsRisk Factorsmedicine.arteryInternal medicineOdds RatiomedicineHumanscardiovascular diseasesMyocardial infarctionBrachial arteryStrokeAgedUltrasonographyCarotid atherosclerosis Endothelial dysfunction Prognosis Risk factorsUnstable anginabusiness.industryAge FactorsGeneral MedicineMiddle Agedmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareVasodilationCarotid Arteriesmedicine.anatomical_structureBlood pressurecardiovascular systemCardiologyFemaleEndothelium Vascularmedicine.symptomTunica IntimaTunica MediaCardiology and Cardiovascular MedicinebusinessBiomarkersFollow-Up StudiesArteryCoronary Artery Disease
researchProduct

Oral Glycoprotein IIb/IIa Antagonists for Unstable Angina — Is There Still a Chance for the Oral Substances?

2001

The intravenous glycoprotein IIb/IIIa antagonists abciximab, tirofiban and eptifibatide are well accepted for the therapy of patients with unstable angina and/or as concomitant medication during coronary interventions. Despite the fact that these drugs are not used in all patients presenting with unstable angina during coronary interventions, the scientific evidence is overwhelming including the substantial reduction in mortality 3 years after utilisation of abciximab for coronary interventions in patients with unstable angina. In addition to these two indications, intravenous glycoprotein IIb/IIIa antagonists are currently being investigated for use in patients undergoing carotid artery in…

Clinical Trials as Topicmedicine.medical_specialtyUnstable anginaFibrinogen receptorbusiness.industryAdministration OralPlatelet Glycoprotein GPIIb-IIIa ComplexHematologyTirofibanmedicine.diseaseAnginaInternal medicinemedicineAbciximabCardiologyEptifibatideHumansAngina UnstableMyocardial infarctionbusinessStrokePlatelet Aggregation Inhibitorsmedicine.drugThrombosis Research
researchProduct

Searching the right coronary artery we found a rare anomaly documented by 3-dimensional volume rendering

2016

Coronary artery anomaliesLipton classificationCoronary angiographyComputed tomography angiography (CTA)3-Dimensional volume rendering (VR)Unstable angina (UA)

Coronary angiographymedicine.medical_specialtybusiness.industryCoronary angiographyCoronary artery anomalieVolume rendering030204 cardiovascular system & hematology3-Dimensional volume rendering (VR)Settore MED/11 - Malattie Dell'Apparato CardiovascolareComputed tomography angiography (CTA)03 medical and health sciences0302 clinical medicineInternal medicineRight coronary arterymedicine.arterymedicineCardiology030212 general & internal medicineAnomaly (physics)businessCardiology and Cardiovascular MedicineSettore MED/36 - Diagnostica Per Immagini E RadioterapiaLipton classificationUnstable angina (UA)
researchProduct